% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Zhang:285005,
author = {Zhang, Lanyue and Antabi, Mohamad Ali and Mattar, Jana and
El Bounkari, Omar and Fang, Rong and Waegemann, Karin and
Bode, Felix J and Stösser, Sebastian and Hermann, Peter and
Liman, Thomas G and Nolte, Christian and Ikenberg, Benno and
Bernkopf, Kathleen and Petzold, Gabor C and Bernhagen,
Jürgen and Dichgans, Martin and Georgakis, Marios K},
collaboration = {Investigators, DEMDAS},
othercontributors = {Endres, Matthias and Düzel, Emrah and Kerti, Lucia and
Neumann, Katja and Meißner, Julius N and Liman, Thomas G.
and Kerti, Lucia and Nolte, Christian H and Wittenberg,
Tatjana and Scheitz, Jan F and Prüß, Harald and Sperber,
Pia Sophie and Nave, Alexander H and Kufner Ibaroule, Anna
and Petzold, Gabor C and Bode, Felix and Stösser, Sebastian
and Meissner, Julius and Ebrahimi, Taraneh and Nordsiek,
Julia and Beckonert, Niklas and Kindler, Christine and Zerr,
Inga and Hermann, Peter and Schmitz, Matthias and Goebel,
Stefan and Bunck, Timothy and Schütte-Schmidt, Julia and
Nuhn, Sabine and Volpers, Corinna and Dechent, Peter and
Bähr, Mathias and Görtler, Michael and Glanz, Wenzel and
Perosa, Valentina and Dichgans, Martin and Wollenweber,
Frank and Georgakis, Marios and Fang, Rong and Janowitz,
Daniel and Waegemann, Karin and Tiedt, Steffen and
Wunderlich, Silke and Ikenberg, Benno and Bernkopf, Kathleen
and Huber, Christiane and Poppert, Holger and Düring, Marco
and Araque Caballero, Miguel Ángel and Gesierich, Benno and
Dewenter, Anna and Dobisch, Laura and Neumann, Katja and
Speck, Oliver and Spottke, Annika and Stöcker, Tony and
Bartenstein, Peter and Wagner, Michael},
title = {{C}irculating cytokine levels and 5-year vascular
recurrence after stroke: {A} multicenter prospective cohort
study.},
journal = {European stroke journal},
volume = {11},
number = {1},
issn = {2396-9873},
address = {London},
publisher = {Sage Publishing},
reportid = {DZNE-2026-00139},
pages = {23969873251360145},
year = {2026},
abstract = {Anti-inflammatory therapies are tested in randomized trials
for secondary stroke prevention. Detecting inflammatory
biomarkers that predict vascular recurrence could optimize
patient selection for these trials.In a multicenter
prospective cohort study, we measured plasma levels of 22
inflammatory cytokines in 486 acute stroke patients (474
ischemic strokes and 12 intracerebral hemorrhages; median
age 68 years, $34\%$ female, median 3 days post-stroke
onset). Patients were followed for over 5 years through
telephone and in-person interviews to record the occurrence
of the following outcomes: (1) recurrent stroke or transient
ischemic attack (TIA; primary outcome); (2) a composite of
recurrent vascular events (stroke, TIA, acute coronary
syndrome, hospital admission due to heart failure, and
death; secondary outcome). Associations between cytokine
levels and these outcomes were analyzed using Cox
proportional hazards models adjusted for demographic and
vascular risk factors.During the 5-year follow-up period, 59
patients $(12.1\%)$ experienced recurrent stroke or TIA, and
118 $(24.3\%)$ experienced recurrent vascular events. After
adjustments for demographic and vascular risk factors, and
correction for multiple comparisons, higher plasma levels of
CD62E (adjusted Hazard Ratio (aHR)/SD increment: 1.63,
$95\%CI$ 1.22-2.20) and MIF (aHR: 1.56, $95\%CI$ 1.18-2.06)
in the acute phase after stroke were statistically
significantly associated with increased risk of recurrent
stroke or TIA. The associations followed a dose-response
pattern across quartiles of CD62E and MIF levels. Adding
baseline CD62E and MIF levels to models including age, sex,
vascular risk factors, and baseline C-reactive protein (CRP)
levels led to significant improvements in the prediction of
5-year risk of recurrent stroke or TIA (ΔC-index
0.030-0.050).Among stroke patients, higher baseline levels
of CD62E and MIF improved prediction of 5-year risk of
recurrent stroke or TIA on top of vascular risk factors and
CRP levels. Whether assessment of these cytokines could
improve patient selection for secondary prevention trials of
anti-inflammatory treatments, should be explored in future
studies.},
keywords = {Humans / Female / Male / Aged / Prospective Studies /
Recurrence / Middle Aged / Cytokines: blood / Ischemic
Attack, Transient: blood / Biomarkers: blood / Stroke: blood
/ Follow-Up Studies / Risk Factors / Ischemic Stroke: blood
/ Cohort Studies / Stroke (Other) / cytokines (Other) /
inflammation (Other) / recurrence (Other) / risk prediction
(Other) / Cytokines (NLM Chemicals) / Biomarkers (NLM
Chemicals)},
cin = {Clinical Research (Munich) / AG Petzold / Clinical Research
(Bonn) / AG Endres / AG Dichgans},
ddc = {610},
cid = {I:(DE-2719)1111015 / I:(DE-2719)1013020 /
I:(DE-2719)1011001 / I:(DE-2719)1811005 /
I:(DE-2719)5000022},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41614521},
doi = {10.1093/esj/23969873251360145},
url = {https://pub.dzne.de/record/285005},
}